[biopharmaceutical list] 2018 China biopharmaceutical R & D strength list was announced!

The "2018 China Pharmaceutical R & D strength ranking" released in the third China Pharmaceutical R & D Innovation Summit includes four lists: general list, chemical medicine list, biological medicine list and traditional Chinese medicine list (click to view other list details) From June 29 to 30, 2018, under the guidance of China Pharmaceutical University, Chongqing Economic and Information Commission, China Association of chemical pharmaceutical industry, and jointly sponsored by yaozhi.com and China Pharmacy magazine, the third China Pharmaceutical R & D Innovation Summit and 2018 top 100 list of China's pharmaceutical R & D strength was held in Chongqing In particular, the 2018 China Pharmaceutical R & D strength ranking was released List (including general list, chemical list, traditional Chinese medicine list, biological medicine list), and award and license for the listed enterprises Heroes from the field of domestic biomedicine gathered at the scene, such as Sichuan Kelun, Lizhu medicine, Zhengda Tianqing, etc (see the table at the end of the paper for 2018 China's biopharmaceutical R & D strength list) potential: in recent years, the policy spring & stock market boom, biopharmaceutics gradually stepped onto the stage of the times, and occupied the market share of drugs in a growing mode year by year In 2017, of the 44 drugs listed in the national medical insurance catalog, 14 were biopharmaceuticals, accounting for about 32% With the increasing proportion of drug development strategy, biopharmaceutics has become the frontier area of active layout of major pharmaceutical enterprises At the same time, the policy orientation also pushes the bio medicine to the upsurge of innovation and development The 13th five year plan for the development of biological industry clearly proposes the construction of a new biomedical system, emphasizing the acceleration of new drug creation and industrialization, the acceleration of the creation of new biological drugs such as antibodies, proteins and peptides, the development of therapeutic vaccines, RNA interference drugs, aptamers, as well as stem cells, chimeric antigen receptor T cell immunotherapy (car-t) and other biological treatment products 。 By virtue of the policy "spring breeze", domestic pharmaceutical enterprises actively layout, take measures such as continuously improving production efficiency, optimizing biological technology, enhancing the R & D strength of technical team, expanding market capacity, etc to strive for the "leading" position of innovative biological drugs, and thus promote the steady development of the whole biological medicine In addition, the pattern of the market economy system in the new era and the market demand for innovative biopharmaceuticals have made the "biopharmaceutical stock" record high, once regarded as the most potential black horse in the pharmaceutical stock; many enterprises scrambled for listing, and in 2017, more than 40 new shares were successfully IPO, a record high After going public, the A-share bio pharmaceutical companies have met the expectations Some of them have a market value of more than 10 billion yuan, and there are 25 companies with main business income of more than 10 billion yuan in 2017, of which Shanghai Pharmaceutical Group Co., Ltd has the most outstanding performance, with a revenue of 130.847 billion yuan A huge amount of revenue is generated from the value of products, while the value of products is derived from continuous innovation In order to maintain the market vitality of the enterprise, continue to absorb the rear financing, make the enterprise stronger and bigger, the listed biomedical enterprises actively plan to continuously expand the R & D investment, add full horsepower to the new drug creation, and promote many new drugs to pile up for clinical application and listing According to drug intelligence data, in 2017, there were 193 applications for review and approval of new biological drugs (calculated by acceptance number, the same below), with a year-on-year growth of about 73.87% Among them, the largest number of applications is 76 new drugs of class 1, followed by 31 new drugs of class 15 and 30 new drugs of class 2 And among the 193 new drugs, 30 are approved for clinical use and 2 for production Top 10: the R & D strength competition is the key chip in the enterprise competition and also the most powerful consideration After 2016 China biopharmaceutical R & D strength ranking and 2017 China biopharmaceutical R & D strength ranking, which "rising rookies" will refresh 2018 China biopharmaceutical R & D strength ranking? The following is a brief look at the changes of the top 10 enterprises in three years (as shown in Table 1) Table 1: Top 10 of 2018, 2017 and 2016 China's biopharmaceutical R & D strength rankings Click to view: the top three of 2017 China's biopharmaceutical R & D strength rankings and 2016 China's biopharmaceutical R & D strength rankings in 2018 are Qilu pharmaceutical, Shanghai Fosun and Shanghai Institute of biological products It can be seen that Qilu Pharmaceutical Co., Ltd has been at the top of the list for two consecutive years, Shanghai Fosun has been ranked second for three years, and kanghino biology has risen to the top 10 in 2018 from 47 in 2016 The competition situation of the R & D strength of Biopharmaceutical Enterprises in China is becoming increasingly fierce New biopharmaceutical companies need to catch up with the situation and improve their own strength to compete with them The king strives for hegemony: in 2017, top three enterprises showed their strength 1 Qilu Pharmaceutical Co., Ltd (hereinafter referred to as Qilu pharmaceutical) is a well-known domestic pharmaceutical enterprise In recent years, Qilu pharmaceutical has been at the forefront of industry development, focusing on the field of biopharmaceutical research and development The forward-looking layout measures not only expanded its product capacity, but also broke the situation that foreign countries monopolized the Chinese market for a long time The successful transformation of Qilu pharmaceutical and the extension of its industrial chain made its 2017 revenue exceed 20 billion yuan At the same time, Qilu pharmaceutical continues to increase its research and development in biological medicine According to the statistics of pharmaceutical intelligence data, Qilu pharmaceutical declared and registered six biological products (see the table below) in 2017, of which five McAbs are the most competitive, and these drugs have been approved for clinical use; pegylated recombinant human granulocyte stimulating factor injection is a supplementary application Table 2: application of Qilu pharmaceutical biological products in 2017 2 Shanghai Fosun Pharmaceutical (Group) Co., Ltd (hereinafter referred to as Shanghai Fosun) has been adhering to the development mode of "endogenous growth, extension expansion and integrated development", with drug manufacturing and research and development as the core According to the 2017 annual report of Shanghai Fosun, the R & D investment in the whole year totaled 1529.2917 million yuan, an increase of 38.26% over 2016 In 2017, there were 171 R & D projects, 10 small molecule innovative drugs, 8 biological innovative drugs and 14 biological similar drugs in Shanghai Fosun The research and development of monoclonal antibody drugs has achieved fruitful results Six monoclonal antibody varieties and 11 indications have been approved in clinical trials in mainland China Three products have entered clinical phase III, and one drug (rituximab injection) applied for production has been included in the priority review process Application list for drug registration Three new monoclonal antibodies, including recombinant anti VEGFR2 all human monoclonal antibody injection and recombinant anti PD-1 humanized monoclonal antibody injection, were approved in clinical trials in the United States and Taiwan Table 3: specific R & D Progress of Shanghai Fosun monoclonal antibody varieties the main deployment of R & D is not limited to monoclonal antibodies, Shanghai Fosun also further enriches and improves the product line in rare diseases, anti-tumor and other fields In 2017, Shanghai Fosun had 8 major R & D projects, 6 drugs (products) applied for clinical application, 1 drug (products) applied for production and 4 drugs (products) with clinical approval (see the table below for details) Table 4: R & D and application of Shanghai Fosun biopharmaceuticals in 2017 3 Shanghai biopharmaceutical Research Institute Co., Ltd (hereinafter referred to as Shanghai biopharmaceutical research institute) was founded in 1949 It is a large state-owned enterprise integrating research, development, production and operation of biopharmaceutical products Its products mainly focus on prevention products, blood products, genetic engineering and diagnostic reagents Shanghai Institute of biological products is a leader in the field of research and development and production of influenza vaccine, and has the courage to break through innovation, accelerate the upgrading of product strategy, and gradually make monoclonal antibody as one of the company's key distribution products According to the pharmaceutical intelligence data, in 2017, Shanghai Institute of biological products applied for 7 new drugs (according to the acceptance number, see the table below), and 2 supplementary applications, including 4 new drugs approved for clinical use It is worth mentioning that there are two McAbs for new drug application, namely, recombinant anti HER2 humanized monoclonal antibody for injection and recombinant human mouse chimeric anti CD20 monoclonal antibody injection Table 5: approval of biopharmaceuticals by Shanghai Institute of biological products in 2017 note: the above enterprise acceptance data is only the data under the name of the enterprise, excluding the data of other name companies belonging to the enterprise If there is any deviation, please forgive me, and welcome to correct and discuss Attachment: 2017 top 50 list of China's biopharmaceutical R & D strength